BACKGROUND: The World Health Organization (WHO) recently recommended that the time to first malaria episode serve as the primary end point in phase III malaria vaccine trials--the first of which will be held in Africa. Although common red blood cell (RBC) polymorphisms such as sickle hemoglobin (HbS) are known to protect against malaria in Africa, their impact on this end point has not been investigated. METHODS: A longitudinal study of 225 individuals aged 2-25 years was conducted in Mali. The association between common RBC polymorphisms and the time to first malaria episode was evaluated. RESULTS: Among children aged 2-10 years, sickle cell trait (HbAS) was associated with a 34-day delay in the median time to first malaria episode (P= .017) Cox regression analysis showed that greater age (hazard ratio [HR], 0.87 [95% CI, 0.80-0.94]; (P= .001), HbAS (HR, 0.48 [95% CI, 0.26-0.91]; (P= .024), and asymptomatic parasitemia at enrollment (HR, 0.35 [95% CI, 0.14-0.85]; (P= .021) were associated with decreased malaria risk. CONCLUSION: Given the delay in the time to first malaria episode associated with HbAS, it would be advisable for clinical trials and observational studies that use this end point to include Hb typing in the design of studies conducted in areas where HbAS is prevalent.
BACKGROUND: The World Health Organization (WHO) recently recommended that the time to first malaria episode serve as the primary end point in phase III malaria vaccine trials--the first of which will be held in Africa. Although common red blood cell (RBC) polymorphisms such as sickle hemoglobin (HbS) are known to protect against malaria in Africa, their impact on this end point has not been investigated. METHODS: A longitudinal study of 225 individuals aged 2-25 years was conducted in Mali. The association between common RBC polymorphisms and the time to first malaria episode was evaluated. RESULTS: Among children aged 2-10 years, sickle cell trait (HbAS) was associated with a 34-day delay in the median time to first malaria episode (P= .017) Cox regression analysis showed that greater age (hazard ratio [HR], 0.87 [95% CI, 0.80-0.94]; (P= .001), HbAS (HR, 0.48 [95% CI, 0.26-0.91]; (P= .024), and asymptomatic parasitemia at enrollment (HR, 0.35 [95% CI, 0.14-0.85]; (P= .021) were associated with decreased malaria risk. CONCLUSION: Given the delay in the time to first malaria episode associated with HbAS, it would be advisable for clinical trials and observational studies that use this end point to include Hb typing in the design of studies conducted in areas where HbAS is prevalent.
Authors: Gerardo Cabrera; Michel Cot; Florence Migot-Nabias; Peter G Kremsner; Philippe Deloron; Adrian J F Luty Journal: J Infect Dis Date: 2005-04-12 Impact factor: 5.226
Authors: Thomas N Williams; Sammy Wambua; Sophie Uyoga; Alex Macharia; Jedidah K Mwacharo; Charles R J C Newton; Kathryn Maitland Journal: Blood Date: 2005-03-15 Impact factor: 22.113
Authors: Thomas N Williams; Tabitha W Mwangi; Sammy Wambua; Neal D Alexander; Moses Kortok; Robert W Snow; Kevin Marsh Journal: J Infect Dis Date: 2005-05-31 Impact factor: 5.226
Authors: Thomas N Williams; Tabitha W Mwangi; Sammy Wambua; Timothy E A Peto; David J Weatherall; Sunetra Gupta; Mario Recker; Bridget S Penman; Sophie Uyoga; Alex Macharia; Jedidah K Mwacharo; Robert W Snow; Kevin Marsh Journal: Nat Genet Date: 2005-10-16 Impact factor: 38.330
Authors: Thomas N Williams; Tabitha W Mwangi; David J Roberts; Neal D Alexander; David J Weatherall; Sammy Wambua; Moses Kortok; Robert W Snow; Kevin Marsh Journal: PLoS Med Date: 2005-05-31 Impact factor: 11.069
Authors: Christophe N Magnan; Michael Zeller; Matthew A Kayala; Adam Vigil; Arlo Randall; Philip L Felgner; Pierre Baldi Journal: Bioinformatics Date: 2010-10-07 Impact factor: 6.937
Authors: Tatiana M Lopera-Mesa; Saibou Doumbia; Drissa Konaté; Jennifer M Anderson; Mory Doumbouya; Abdoul S Keita; Seidina A S Diakité; Karim Traoré; Michael A Krause; Ababacar Diouf; Samuel E Moretz; Gregory S Tullo; Kazutoyo Miura; Wenjuan Gu; Michael P Fay; Steve M Taylor; Carole A Long; Mahamadou Diakité; Rick M Fairhurst Journal: Lancet Haematol Date: 2015-03-24 Impact factor: 18.959
Authors: Peter D Crompton; Matthew A Kayala; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta E Weiss; Douglas M Molina; Chad R Burk; Michael Waisberg; Algis Jasinskas; Xiaolin Tan; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; David L Narum; Xiaowu Liang; Ogobara K Doumbo; Louis H Miller; Denise L Doolan; Pierre Baldi; Philip L Felgner; Susan K Pierce Journal: Proc Natl Acad Sci U S A Date: 2010-03-29 Impact factor: 11.205
Authors: Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422
Authors: Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura Journal: J Infect Dis Date: 2013-03-28 Impact factor: 5.226
Authors: Greta E Weiss; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; Seydou Dia; Agnes Guindo; Abdramane Traore; Chiung-Yu Huang; Kazutoyo Miura; Marko Mircetic; Shanping Li; Amy Baughman; David L Narum; Louis H Miller; Ogobara K Doumbo; Susan K Pierce; Peter D Crompton Journal: PLoS Pathog Date: 2010-05-20 Impact factor: 6.823